These are news releases that are related to our Investor efforts. Releases are listed in chronological order and are archived by year. Sign-up to receive news as it is released using the email and RSS tools below.
Mar 27, 2017Therapix Biosciences Ltd. Announces Closing of U.S. Initial Public Offering of American Depositary Shares2,000,000 American Depository Shares Priced at $6.00 per ADS
Tel-Aviv, Israel, March 27, 2017 – Therapix Biosciences Ltd. (NASDAQ: TRPX, TASE: THXBY), a specialty clinical-stage pharmaceutical company specializing in the development of cannabinoid-based...
Mar 22, 2017
Tel Aviv, Israel, March 22, 2017 – Therapix Biosciences Ltd. (NASDAQ:TRPX) (TASE: THXBY), a specialty clinical-stage pharmaceutical company specializing in the development of cannabinoid-based...
Mar 10, 2017Therapix and Rafa signed a Memorandum of Understanding for the formation of a venture to research and develop a cannabinoid-based drug for treating toothaches and periodontal diseases
Therapix Biosciences (OTC: THXBY) (TASE: THXBY.TA), a pharma company specializing in the development of cannabinoid-based drugs, signed a non-binding Memorandum of Understandings (MOU) for a...
Feb 16, 2017
Therapix Biosciences, a clinical-stage pharma company specializing in the development and commercialization of cannabinoid-based drugs announced that it entered into an agreement with a private...
Jan 4, 2017Therapix Biosciences announces enrollment of the first patient for clinical trial at Yale University for treating Tourette’s syndrome using cannabinoid-based drugA translation of the Tel Aviv Stock Exchange (TASE) Immediate Release
The Company respectfully updates, that it was informed that on December 23, 2016, the first subject was enrolled into the proof-of-concept phase IIa clinical trial of the drug developed by the...